ProQR Therapeutics NV

How big is ProQR Therapeutics NV?

As of Jun 18, ProQR Therapeutics NV has a market capitalization of 205.86 million, with net sales of 20.36 million and a net profit of -32.35 million over the latest four quarters. The company reported shareholder's funds of 91.70 million and total assets of 173.92 million as of Dec 24.

Market Cap: As of Jun 18, ProQR Therapeutics NV has a market capitalization of 205.86 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ProQR Therapeutics NV reported net sales of 20.36 million and a net profit of -32.35 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 91.70 million and total assets of 173.92 million.

What does ProQR Therapeutics NV do?

ProQR Therapeutics N.V. is a pre-clinical biopharmaceutical company focused on developing RNA-based therapies for severe genetic disorders. As of March 2025, it has a market cap of $205.86 million, with net sales of $5 million and a net loss of $11 million.

Overview: <BR>ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for severe genetic disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 205.86 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.62 <BR>Return on Equity: -38.80% <BR>Price to Book: 2.41<BR><BR>Contact Details: <BR>Address: Zernikedreef 9, LEIDEN None: 2333 CK <BR>Tel: 31 854 894932 <BR>Website: https://www.proqr.com/

Who are in the management team of ProQR Therapeutics NV?

As of March 2022, the management team of ProQR Therapeutics NV includes Mr. Dinko Valerio (Chairman) and five independent members: Mr. Bart Filius, Ms. Theresa Heggie, Ms. Alison Lawton, M. Antoine Papiernik, and Dr. James Shannon, who oversee the company's strategic direction and governance.

As of March 2022, the management team of ProQR Therapeutics NV includes the following members of the Board of Directors:<BR><BR>- Mr. Dinko Valerio, Independent Chairman of the Supervisory Board<BR>- Mr. Bart Filius, Independent Member of the Supervisory Board<BR>- Ms. Theresa Heggie, Independent Member of the Supervisory Board<BR>- Ms. Alison Lawton, Independent Member of the Supervisory Board<BR>- M. Antoine Papiernik, Independent Member of the Supervisory Board<BR>- Dr. James Shannon, Independent Member of the Supervisory Board<BR><BR>This team is responsible for overseeing the company's strategic direction and governance.

Should I buy, sell or hold ProQR Therapeutics NV?

Is ProQR Therapeutics NV overvalued or undervalued?

As of November 4, 2021, ProQR Therapeutics NV is considered risky and overvalued, with key financial metrics indicating challenges in profitability, despite a strong 3-year return of 192% that has been overshadowed by a year-to-date decline of 17.36%.

As of 4 November 2021, the valuation grade for ProQR Therapeutics NV moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.44, an EV to EBIT of -1.92, and an EV to Sales ratio of 3.42, which indicate significant challenges in profitability and valuation relative to its sales.<BR><BR>In comparison to its peers, ProQR Therapeutics NV has a P/E ratio of -5.81, while Esperion Therapeutics, Inc. has a P/E of -4.99, and Ocugen, Inc. stands at -5.65, all reflecting a risky valuation environment in the biotechnology sector. Despite a strong 3-year return of 192.0%, which outperformed the S&P 500's 70.41% return, the year-to-date performance of -17.36% suggests ongoing struggles that reinforce the notion of overvaluation.

Is ProQR Therapeutics NV technically bullish or bearish?

As of September 11, 2025, ProQR Therapeutics NV shows a mildly bullish trend with mixed technical indicators, including a bullish weekly MACD and mildly bearish monthly KST, while year-to-date performance is -17.36%, underperforming the S&P 500, but it has outperformed the index over the past year with a 21.67% return.

As of 11 September 2025, the technical trend for ProQR Therapeutics NV has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The Bollinger Bands also reflect a mildly bullish stance on both weekly and monthly time frames. However, the KST shows a bullish weekly signal but is mildly bearish monthly, and Dow Theory indicates a mildly bearish stance on both time frames. The daily moving averages are mildly bullish, suggesting short-term support.<BR><BR>In terms of performance, ProQR has a year-to-date return of -17.36%, underperforming the S&P 500's 12.22%, but it has outperformed the index over the past year with a return of 21.67% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but with mixed signals from various indicators.